1 / 22

Pain and Chemical Dependency

Pain and Chemical Dependency. Not an “Either – Or” proposition Douglas Gourlay, MD, FRCPC, FASAM Wasser Pain Centre, Toronto ON. The Problem. Pain and Addiction CAN coexist Addiction in General Population Varies 3 – 16% prevalence Varies with the drug, gender, economic status, race, age…

lkinsey
Télécharger la présentation

Pain and Chemical Dependency

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pain and Chemical Dependency Not an “Either – Or” proposition Douglas Gourlay, MD, FRCPC, FASAM Wasser Pain Centre, Toronto ON

  2. The Problem • Pain and Addiction CAN coexist • Addiction in General Population • Varies 3 – 16% prevalence • Varies with the drug, gender, economic status, race, age… • Addiction in the Chronic Pain Population • We really have no idea • We use the same terms, with different meaning • Lack of precision in definitions around abuse/dependency/addiction DL Gourlay, MD, FRCPC, FASAM

  3. Definitions • Addiction:Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. (LCPA) DL Gourlay, MD, FRCPC, FASAM

  4. Definitions • Physical Dependence: Physical dependence is a state of adaptation that often includes tolerance and is manifested by a drug class specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist. (LCPA) DL Gourlay, MD, FRCPC, FASAM

  5. Definitions • Tolerance:Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug's effects over time. • Tolerance develops at different rates, in different people, to different effects DL Gourlay, MD, FRCPC, FASAM

  6. Definitions • Pseudoaddiction:Iatrogenic, maladaptive behavior resulting from inadequate pain control • Not to be used “instead of” addiction • Unwise to diagnose in patient with history of addictive disorder, even in other substance DL Gourlay, MD, FRCPC, FASAM

  7. Addiction * Environment * Biology Drug DL Gourlay, MD, FRCPC, FASAM

  8. Diagnosis • DSM-IV criteria - dependence • Maladaptive behavior having at least three of the following in a 12 month period • Withdrawal • Tolerance • Use in larger amounts or over longer period than intended • Persistent use, or unsuccessful attempts to cut-down or control use • XS time spent using or recovering from use • Narrowing of focus due to substance use • Continued use despite harm DL Gourlay, MD, FRCPC, FASAM

  9. Pain and Addictionas Co-morbid Conditions • Pain often complicate the Dx of Addiction • Pain and Addiction can coexist • Pain plus • Alcoholism • Cocaine • Cannabis • Relatively simple to use current tools to assess addiction i.e. DSM-IV DL Gourlay, MD, FRCPC, FASAM

  10. Pain and Opioid Addiction • What happens when the ‘drug of choice’ is both the problem AND the solution, depending on point of view? • Addiction Specialist • Aberrant behavior is due to opioid abuse/addiction • Pain Specialist • Aberrant behavior is due to inadequate treatment of pain (pseudoaddiction) DL Gourlay, MD, FRCPC, FASAM

  11. Patient Addiction Pain Patient Patient Pain-Addiction Continuum DL Gourlay, MD, FRCPC, FASAM

  12. Boundary Setting • 90%+ of patients don’t need strict boundary setting • Most patients have their own internal set • For remaining ~10%, strict boundary setting is essential • Treatment Agreements, Urine Testing, interval / contingency dispensing DL Gourlay, MD, FRCPC, FASAM

  13. Boundaries – Identification and Enforcement Discharge Patient DL Gourlay, MD, FRCPC, FASAM

  14. Boundaries – Identification and Enforcement Consultation with Addiction Medicine DL Gourlay, MD, FRCPC, FASAM

  15. Selling prescription drugs Prescription forgery Stealing or “borrowing” drugs from another patient Injecting oral formulations Obtaining prescription drugs from non-medical sources Concurrent abuse of related illicit drugs Multiple unsanctioned dose escalations Repeated episodes of lost prescriptions Aggressive complaining about the need for higher doses Drug hoarding during periods of reduced symptoms Requesting specific drugs Prescriptions from other physicians Unsanctioned dose escalation Unapproved use of the drug Reporting psychic effects not intended by the physician Aberrant Drug-Related Behaviors More Predictive Less Predictive Jaffee, 1996 DL Gourlay, MD, FRCPC, FASAM

  16. Assessing Aberrant Behavior • What does it mean? • Aberrant behavior is a late and often unreliable sign of an addictive disorder • When used to trigger UDT, more often used in punitive fashion • Aberrant behavior does NOT equal inadequate pain management in all patients DL Gourlay, MD, FRCPC, FASAM

  17. Assessment Strategies • 1st address pain complaints • Explore AM pain and role of IR opioids • Carefully document medication use • Dosing intervals, what worked, what didn’t • Lost/stolen, early refills, double doctoring, problems with control, withdrawal symptoms • Family history of drug/EtOH problems • Personal psychiatric history DL Gourlay, MD, FRCPC, FASAM

  18. Assessment Strategies • Personal Substance Use History • Alcohol, tobacco, street drugs • Time of last use • Drug Treatment History • Legal Issues • Social • Physical Examination • Lab Tests: Liver, Hepatitis, HIV, CBC, UDS DL Gourlay, MD, FRCPC, FASAM

  19. Pain and Chemical DependencyProgram • Pain and CD Clinic CAMH • Initially at the AMC • Problems with stigma (many “no show’s”) • Pain and CD division at the Wasser • Easier for patients to comfortably attend • Very few patients fail to attend appointments • But difficult to manage dominant SUD pts • “Easier to teach pain docs about addiction” DL Gourlay, MD, FRCPC, FASAM

  20. Pain and Chemical DependencyProgram • Strong bridge between the Wasser Pain Centre and CAMH was needed • Currently fellows and residents from CAMH spend time at the Wasser Clinic on Thursday • Queen Street Lab does UDT for Wasser • Stabilized Pain and CD pts are seen at Wasser • But we don’t have a place to manage complex pharmacotherapy problems; we’re not integrated DL Gourlay, MD, FRCPC, FASAM

  21. Pain and Chemical DependencyProgram • 2004, Purdue Canada donated $300,000 over 3 yrs for a Pain and CD division at the Wasser Pain Management Centre • We are now discussing possibilities of having a “Rationalization of Pharmacotherapy Unit” at the Donwood Site • Pts will be assessed and medically stabilized before deciding what services might next be offered DL Gourlay, MD, FRCPC, FASAM

  22. Conclusions • Pain and Addiction can coexist • Successful treatment of either often requires assessment and management of both • The Pain and CD Division of the Wasser Pain Centre will do what neither CAMH nor Wasser could do alone DL Gourlay, MD, FRCPC, FASAM

More Related